17th Jun 2016 11:21
LONDON (Alliance News) - Summit Therapeutics PLC said Friday that it has enrolled the first patient in its phase II proof of concept trial of ezutromid in patients with Duchenne muscular dystrophy.
Summit expects to periodically report data during this trial, with 24 week muscle biopsy data from the first group of patients enrolled expected to be reported in January 2017.
"Ezutromid has garnered considerable interest from the patient, family and healthcare communities, which we believe is due to its potential to slow or stop progression of DMD regardless of the underlying dystrophin gene mutation," said Chief Medical Officer Ralf Rosskamp in a statement.
"The enrolment of the first patient in PhaseOut DMD is a significant milestone in the clinical development of ezutromid, with the aim of studying long-term dosing of ezutromid in boys with DMD. We look forward to the possibility of demonstrating ezutromid's effect on utrophin with the initial set of 24-week biopsy data," Rosskamp added.
Shares in Summit were up 2.9% at 108.00 pence Friday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
SUMM.L